Introduction
============

Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are the most common diseases of the prostate; however, their interaction is not well studied.[@b1-rru-8-201],[@b2-rru-8-201] Historically, elucidating the epidemiology of BPH has been complicated by the lack of a uniform definition of clinical BPH, quantitative instruments for assessing the severity of lower urinary tract symptoms, and a noninvasive and accurate method for measuring both prostate volume and bladder outlet obstruction. Several investigators in different countries found that the prevalence of clinical BPH is fairly uniform worldwide and also consistently age related.[@b1-rru-8-201] Symptomatic BPH affects \~20% of men in the age-group of 50--59 years, 30% of men in the age-group of 60--69 years, and 40% of men in the age-group of 70 years and older.[@b3-rru-8-201]

Currently, PCa also remains a significant burden in the health of older men. PCa is the most commonly diagnosed non-skin cancer in men, accounting for 21% of newly diagnosed non-skin cancers in 2016; this amounts to 180,890 new cases of PCa, including 26,120 deaths in 2016.[@b4-rru-8-201]

Prostate-specific antigen (PSA) is a widely used, albeit controversial, diagnostic tool in the detection of PCa. Serum PSA levels of \>4.0 ng/mL has a sensitivity of \~20% and a specificity in the range of 60--70%.[@b5-rru-8-201] The low sensitivity may be due to the fact that PSA serum levels can be elevated in the presence of benign pathology such as BPH and prostatitis.

Recent clinical studies have shown that there may be an association between prostate volume and the incidence of PCa.[@b2-rru-8-201],[@b6-rru-8-201]--[@b9-rru-8-201] In this context, we performed a study to further elucidate the relationship between prostate volume and the incidence of PCa.

Patients and methods
====================

A cohort of 448 men were seen and evaluated at the Urology Clinic of Texas Tech Physicians in Lubbock, TX, USA, from 2008 to 2013. Patients who never had a biopsy with PSA levels of \>4 ng/mL or with suspicious findings on digital rectal examination (DRE) were included in our study. For each patient prior to performing a warranted prostate biopsy, a complete history was collected and physical examination was performed. The prostate volume for each patient was estimated by DRE and confirmed by transrectal ultrasound (TRUS). Patients who underwent prior biopsies or prior surgeries were excluded from our study. For each prostate, 12-core TRUS-guided biopsies were performed bilaterally, including at the apex, base, and middle portion of the gland. A minimum of six biopsies were performed in each lobe in addition to biopsies obtained if suspicious lesions were encountered. PSA density data were obtained by dividing the PSA serum level by the TRUS-confirmed prostate volume.

The Texas Tech University Health Sciences Center Institutional Review Board For The Protection Of Human Subjects approved the study (IRB: L14-107). Due to the retrospective nature of the study the review board waived the need for patient written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization. Statistical analysis was performed by Statistical Analysis System program, Windows 9.1.3.

Results
=======

Of the 442 patients who underwent prostate biopsy, 244 patients (55.2%) were found to have a positive biopsy result. The rate of positive biopsy correlated with an increase in age: 48.28% in the age range of 40--54 years inclusively, 53.87% in the age range of 55--69 years inclusively, and 61.9% in the age range of 70 years and older ([Table 1](#t1-rru-8-201){ref-type="table"}). In addition, mean Gleason score, representing the aggressiveness of the diagnosed PCa, had a similar relationship with respect to increasing age. Distribution of PSA, DRE-determined volume, and TRUS-determined volume are graphically represented in [Figure 1](#f1-rru-8-201){ref-type="fig"}.

Next, we determined the positive biopsy rates with respect to prostate volume. Prostates with a positive biopsy were divided into three groups based on prostate volume: prostates \<35 cc, prostates between 35 and 65 cc, and prostates \>65 cc. The results are shown in [Figure 2](#f2-rru-8-201){ref-type="fig"}. The positive biopsy rate was 66% for patients with a prostate volume of ≤35 cc and 40% for patients with a prostate volume of ≥65 cc (*P*\<0.001).

We then determined the Gleason scores for prostates with a volume of \<35 and \>65 cc. The results are shown in [Table 2](#t2-rru-8-201){ref-type="table"}. Of the 110 patients testing positive on biopsy with a volume of \<35 cc, 10 patients (9.09%) had a Gleason score of ≥8. Of the 27 patients testing positive on biopsy with a volume of \>65 cc, 1 patient (3.7%) had a Gleason score of ≥8.

Discussion
==========

Several studies have demonstrated a relationship between prostate volume and the incidence of PCa.[@b2-rru-8-201],[@b6-rru-8-201]--[@b9-rru-8-201] These studies have shown an inverse relationship between prostate volume and the incidence of PCa; as prostate volume increases, incidence of PCa decreases. Our results exhibit a similar relationship as indicated in [Figure 2](#f2-rru-8-201){ref-type="fig"}. Prostate volume of ≤35 cc had a 66% positive biopsy rate, whereas prostate volume of ≥65 cc had a 40% positive biopsy rate, ie, a reduction of 39.4%. A recent study described an inverse relationship between prostate symptom score and PCa.[@b10-rru-8-201] Since a prostate symptom score would correlate with prostate volume, this pattern would be expected when compared with the studies mentioned earlier.[@b2-rru-8-201],[@b6-rru-8-201]--[@b9-rru-8-201] However, this study could not show an increase in the accuracy of cancer detection in the multivariate analysis.[@b10-rru-8-201] Another study has shown an association between prostate volume and high-grade advanced PCa.[@b11-rru-8-201] A recent publication examined the association of PCa volume and prostate size. Their data showed that small-volume cancers (\<0.5 g) were twice as common in larger glands (\>50 g) compared to smaller glands (\<50 g). This may imply that PCa may spread with less difficulty in smaller glands.[@b9-rru-8-201],[@b11-rru-8-201] In another recent prospective study, a large cohort of 1,044 men underwent multiparametric magnetic resonance imaging (MRI) and then 12-core systemic mapping biopsy with additional MRI--fusion ultrasound (US) biopsy if the previous MRI had detected suspicious lesions of the prostate. This large study also revealed an inverse association of prostate volume with incidence and higher Gleason score (\>7) for PCa.[@b12-rru-8-201] The above-mentioned studies, in addition to the results of our study, support the hypothesis of an inverse association between prostate volume and the incidence of PCa. Furthermore, the results in [Table 2](#t2-rru-8-201){ref-type="table"} illustrate a reduction in high-grade PCa (Gleason score of ≥8) in larger prostates (volume \>65 cc). Out of 110 biopsy-positive patients with prostates of \<35 cc, 10 patients had a Gleason score of ≥8 (9.1%). However, out of 27 biopsy-positive patients with prostates of \>65 cc, only 1 patient had a Gleason score of ≥8 (3.7%). This is a reduction of 59.3% in high-grade cancers when comparing prostates to a volume of \<35 and \>65 cc. Therefore, our results show that not only the incidence but also the aggressiveness of PCa decreases in larger prostates.

Other previous clinical studies have also described the phenomenon of decreased cancer detection rates in larger prostates.[@b11-rru-8-201],[@b13-rru-8-201]--[@b15-rru-8-201] The authors debated that increased prostate volume makes it more difficult to detect same-size cancer lesions with the biopsy needle compared to smaller prostates with the same cancer volume lesions. These authors labeled this issue of lower PCa detection rates in enlarged prostates as the so-called sampling error.[@b13-rru-8-201] Recently, TRUS-guided biopsy was believed to be the limiting factor in the detection of PCa in larger prostates as 12-core TRUS biopsies may under-sample large glands. Thus, prostate biopsy protocols have evolved during the recent years toward protocols that propose increasing the number of biopsies. Several studies have shown PCa detection rates of \~40% or less in men with a prostate volume of \>50 cc, while, and in contrast, detection rates were much higher in smaller glands.[@b16-rru-8-201],[@b17-rru-8-201] In the past few years, the MRI--TRUS fusion imaging with targeted biopsies has evolved overcoming the limitations of the TRUS-guided biopsy technique, in particular, for larger prostates. De Gorski et al[@b7-rru-8-201] describe the improved detection rate for this malignancy in larger prostates compared to US-guided biopsies alone. In this study, the detection rate for MRI--TRUS-fusion-guided biopsy was 77% in prostate glands with a volume of \<30 cc, compared to 61%, 47%, and 34% for glands with a volume of 30 to \<38.5 cc, 38.5 to \<55 cc, and \>55 cc, respectively.[@b17-rru-8-201] These results were statistically significant (*P*=0.001). These data are similar and correspond well with the results described in our study (66.27% in prostates \<35 cc and 40.9% in glands \>65 cc). Thus, the finding that MRI--TRUS fusion imaging improved the detection of suspicious prostate lesions and was not impaired by prostate size endorses the assumption of inverse correlation between prostate volume and cancer incidence. Therefore, the argument that this observed association between prostate volume and the incidence of cancer is due to sampling error may be contested.[@b12-rru-8-201]

Studies have shown that 80% of PCa arises in the peripheral zone (PZ), whereas BPH is caused by growth of the transition zone (TZ).[@b18-rru-8-201] To the experienced urologists, it is a well-known phenomenon in open surgical treatment of large BPH glands with a size of \>80--90 cc that the continuous growth of the TZ compresses the PZ and thus creates the so-called surgical capsule of the prostate, which enables enucleating the BPH component and leaving the collagen-rich and cell-deprived surgical capsule behind.[@b19-rru-8-201] The clinical question arises whether the BPH-related TZ enlargement could cause enough atrophy, scarring, and apoptosis of the epithelial cells in the PZ and thus significantly reduce the risk of developing adenocarcinoma of the prostate in the remaining epithelial glands. This might explain the reduced detection rate of PCa in large prostates as outlined earlier.

Limitations
===========

We report in this study a retrospective data review, which has several limitations including its single-center design, the lack of rationale for prostate volume ranges, the limited sample size of larger prostate volume, and the uneven distribution of cases according to the selected prostate volume ranges. Furthermore, without evaluating the whole-mount prostatectomy specimens for those patients who underwent surgery, the difference in accuracy between prostate biopsies and the final pathology findings of the entire gland specimen could not be determined.

Conclusion
==========

The results of this study depict an inverse association of prostate volume with the incidence and biological aggressiveness of PCa. Data from this study and the outlined discussion should encourage other clinicians and investigators to further explore the relationship between prostate volume and the incidence and aggressiveness of PCa, to further investigate this phenomenon. This, in turn, may have future clinical implications.
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**Note:** Cases with subsequently proven metastatic disease were excluded.\
**Abbreviations:** DRE, digital rectal examination; PSA, prostate-specific antigen; TRUS, transrectal ultrasound.](rru-8-201Fig1){#f1-rru-8-201}

![Categorical breakdown by prostate volume.\
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###### 

Clinical parameters of patients undergoing prostate biopsies

  Parameters                                              40--54 years   55--69 years   70+ years    Total         *P*-value
  ------------------------------------------------------- -------------- -------------- ------------ ------------- ------------
  Number of patients                                      58             271            113          442           
  Positive biopsies, n (%)                                28 (48.28)     146 (53.87)    70 (61.90)   244 (55.20)   *P*\<0.001
  Mean Gleason score                                      6.57           6.71           6.86         6.74          *P*\<0.025
  Abnormal DRE[a](#tfn1-rru-8-201){ref-type="table-fn"}   60%            64.40%         69.52%       65.76%        
  Mean DRE-estimated volume (mL)                          32.04          36.99          41.51        37.46         *P*\<0.05
  Mean TRUS-determined volume (mL)                        31.32          42.89          52.03        43.62         *P*\<0.05
  Mean PSA                                                8.91           14.05          19.45        11.78         *P*\<0.05
  Median PSA                                              5.4            6.2            7.3          6.3           
  Patients with a family history                          28%            17.09%         16.13%       19.67%        

**Note:**

Abnormal DRE is defined as increased size of \>30 g, nodules, or induration.

**Abbreviations:** DRE, digital rectal examination; PSA, prostate-specific antigen; TRUS, transrectal ultrasound.

###### 

Gleason scores by prostate volume

  Parameters                              Volume \<35 cc   Volume \>65 cc   *P*-value
  --------------------------------------- ---------------- ---------------- ------------
  Number of patients                      166              66               
  Biopsy-positive patients, n (%)         110 (66.27)      27 (40.9)        *P*\<0.001
  Patients with Gleason score ≤7, n (%)   100 (90.9)       26 (96.29)       *P*\<0.03
  Patients with Gleason score ≥8, n (%)   10 (9.09)        1 (3.7)          
